Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Cambridge Advisors Inc.

Cambridge Advisors Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,387 shares of the medical research company’s stock after buying an additional 114 shares during the quarter. Amgen makes up about 1.8% of Cambridge Advisors Inc.’s holdings, making the stock its 14th largest position. Cambridge Advisors Inc.’s holdings in Amgen were worth $8,180,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Fifth Third Wealth Advisors LLC raised its stake in Amgen by 147.0% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 2,280 shares of the medical research company’s stock valued at $648,000 after purchasing an additional 1,357 shares during the last quarter. Capital Asset Advisory Services LLC raised its stake in Amgen by 18.7% in the 1st quarter. Capital Asset Advisory Services LLC now owns 1,759 shares of the medical research company’s stock valued at $475,000 after purchasing an additional 277 shares during the last quarter. Harbour Capital Advisors LLC raised its stake in Amgen by 5.2% in the 1st quarter. Harbour Capital Advisors LLC now owns 1,146 shares of the medical research company’s stock valued at $317,000 after purchasing an additional 57 shares during the last quarter. Norway Savings Bank raised its stake in Amgen by 25.9% in the 1st quarter. Norway Savings Bank now owns 3,111 shares of the medical research company’s stock valued at $885,000 after purchasing an additional 640 shares during the last quarter. Finally, New England Research & Management Inc. raised its stake in Amgen by 54.4% in the 1st quarter. New England Research & Management Inc. now owns 8,953 shares of the medical research company’s stock valued at $2,546,000 after purchasing an additional 3,153 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AMGN shares. Morgan Stanley cut their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price objective on shares of Amgen in a report on Thursday, September 26th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price objective (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Truist Financial lowered shares of Amgen from a “buy” rating to a “hold” rating and increased their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $332.55.

Amgen Stock Up 0.3 %

Shares of NASDAQ:AMGN opened at $315.69 on Friday. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The company has a 50 day moving average of $325.77 and a two-hundred day moving average of $313.12. The company has a market capitalization of $169.35 billion, a price-to-earnings ratio of 45.10, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the business earned $5.00 EPS. The firm’s revenue was up 20.1% compared to the same quarter last year. As a group, analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.85%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.